Business
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics ProductionMELBOURNE, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a Contract and Development Manufacturing Organization (CDMO) has been engaged for the GMP manufactur
About this update from Propanc Biopharma, Inc.
[{"type":"image","alt":"Propanc Biopharma, Inc.","displaySize":"","headline":null,"caption":"Propanc Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/1d46ee439e4fd6f462d5d9ac2d16195b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3CVW7M..8.qp0Zog.Hg.9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1/https://media.zenfs.com/en/globenewswire.com/1d46ee439e4fd6f462d5d9ac2d16195b","width":300,"height":68},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/3CVW7M..8.qp0Zog.Hg.9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1/https://media.zenfs.com/en/globenewswire.com/1d46ee439e4fd6f462d5d9ac2d16195b","width":300,"height":68}},"lazy":false},{"type":"text","content":"Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production","length":127,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a Contract and Development Manufacturing Organization (CDMO) has been engaged for the GMP manufacture of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. Based in Europe, the CDMO provides end-to-end services for preclinical and clinical projects, with extensive experience in decoding biologics production (plasmid DNA and recombinant proteins) providing services of cell line generation, banking and characterization, analytical development, process development and batches production of both drug substances and drug products (decoding biologics production refers to the specialized process of understanding, optimizing, and controlling the manufacturing of complex medicines derived from living cells, such as proteins, vaccines, and monoclonal antibodies).","length":1139,"tagName":"p"},{"type":"text","content":"“After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study which we plan to file the clinical trial application for later this year. Further, I am confiden...